Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.

ClinicalTrials.gov 8 recruiting now early-phase tilt small index

Heart Failure NYHA Class III: early-phase trial registry

8 of 10 indexed Heart Failure NYHA Class III trials are currently recruiting, with more weight in Phase 1-2.

Corpus placement: #1,724 of 28,707 conditions by registered trial count.

Jump to open trials → Trial finder

10 US clinical trials · 8 currently recruiting · #1,724 of 28,707 conditions by registered trial count

Heart Failure NYHA Class III: 10 US clinical trials tracked, 8 recruiting.

Heart Failure NYHA Class III is the subject of 10 registered US clinical trials on ClinicalTrials.gov, 8 of them currently open to new participants. 0 are in Phase 3-4 (later-stage) and 2 in Phase 1-2 (earlier-stage). The most active sponsor is Endotronix, running 3 of these trials.

Enrollment posture brief

Registry condition heart-failure-nyha-class-iii

OPEN 8 | RECR 80% | LATE 0 | EARLY 2 | RANK #1724 | SPON 3

Volume-matched condition peers

Nearest open-share peer: Ablation (80% recruiting · 5 trials)

Acute Leukemia of Ambiguous 80%Heart Failure NYHA Class (th…80%Achondroplasia40%Accelerated Phase Chronic My20%Accidental Fall20%
Open-enrollment share among volume-matched conditions near Heart Failure NYHA Class III

Heart Failure NYHA Class III lists 8 open slots (80% of 10 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →

Key findings

What ClinicalTrials.gov does not surface for Heart Failure NYHA Class III on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.

  1. Heart Failure NYHA Class III is recruiting above its size-band peers.

    8 of 10 indexed trials (80%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.

  2. One sponsor concentrates Heart Failure NYHA Class III research.

    Endotronix accounts for 3 of 10 trials (30%). 8 distinct sponsors appear on at least one study for this condition label.

  3. Typical Heart Failure NYHA Class III enrolment sits around 280 participants.

    Median target enrolment is 280 among the 10 trials that report a genuine target (sentinel values excluded). 4 of those (40%) plan for fewer than 100 participants.

  4. Heart Failure NYHA Class III research is mostly interventional.

    9 interventional and 1 observational studies make up this index (90% interventional). Study type is sponsor-reported on ClinicalTrials.gov.

Phase 11Phase 21

Phase Distribution

PhaseTrial count
Phase 1 1
Phase 2 1

Top Sponsors

Endotronix 3 trials
InterShunt Technologies 1 trials
HeartWorks 1 trials
Abbott Medical Devices 1 trials
Northwell Health 1 trials
West Virginia University 1 trials
University of Washington 1 trials
Massachusetts General Hospital 1 trials

Named interventions

Most-linked intervention names on Heart Failure NYHA Class III records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.

Cordella™ Pulmonary Artery Sensor System Device
2 trials
CardioMEMS™ HF System Device
1 trials
Tricuspid Valve Repair (TVR) Procedure
1 trials
Left ventricular assist device (LVAD) Device
1 trials
HF-FamPALhomeCARE Behavioral
1 trials
iPSC-CL Biological
1 trials
BaroStim Device
1 trials
PAS-C System Device
1 trials

US sites by state

Facility locations filed on Heart Failure NYHA Class III trials. A trial with sites in several states counts in each.

California 4 trials
Illinois 3 trials
Arizona 3 trials
Minnesota 2 trials
Massachusetts 2 trials
Indiana 2 trials
Georgia 2 trials
Florida 2 trials

Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.

Related

Read our methodology - how this data is sourced, computed, and verified.

What to do with this Heart Failure NYHA Class III page

10 registered trials, 8 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.

  • 8 Heart Failure NYHA Class III trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
  • Endotronix sponsors the most Heart Failure NYHA Class III trials on record, review their full trial history before evaluating a specific study. See Endotronix's trials
  • Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Heart Failure NYHA Class III condition card totals 10 registered trials; most-linked intervention Cordella™ Pulmonary Artery Sensor System; top US site state California. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.